The headline everyone wants to write is wrong
It would be easy to say NMN "protects the heart from low oxygen." That is not what this new mouse study found. The result is more mixed, and more interesting.
In a 2026 paper in Nutrients, researchers tested whether nicotinamide mononucleotide (NMN), a popular NAD+ precursor, could blunt the damage caused by intermittent normobaric hypoxia. This is a repeated-low-oxygen model that loosely echoes sleep apnea and some altitude-training protocols. NMN did not prevent cardiac hypertrophy. It did, however, lower two molecular markers of heart stress, shift the spleen back toward normal, and change the gut microbiota. It also pushed one blood-damage marker the wrong way.
- PubMed: PMID 42942905
- DOI: 10.3390/nu18203334
- Authors: Wang Z, Wang M, Guo J, Wang Y, Wang S, Yuan J, Yang R, Bi Y, Ke Y.
Important up front: this is an animal-only study, and the authors themselves call the results exploratory.
What the researchers did
Mice were randomly assigned to one of three groups:
- Normoxia, normal oxygen, the control group
- Intermittent normobaric hypoxia, repeated low-oxygen exposure at normal air pressure
- Hypoxia plus NMN, the same exposure with NMN given
The team then looked at organ indices (organ weight relative to body size), blood measures, tissue histopathology, and gut microbiota using 16S rRNA gene amplicon sequencing.
The abstract does not give the NMN dose, route, duration, or the number of animals. Check the full paper before drawing any conclusions about how the experiment was run.
What hypoxia did to the mice
The low-oxygen exposure did real damage. Compared with normoxia, it significantly increased:
- Heart weight and cardiac index
- Right ventricular weight and index
- Spleen index
- Serum lactate dehydrogenase (LDH) activity, a general marker of tissue stress or injury
- Cardiac expression of BNP and Myh7
The authors read this as pathological cardiac hypertrophy plus activation of a ventricular stress response. BNP is a well-known heart-strain marker. Myh7 encodes a myosin isoform that tends to be switched on when the heart is under pathological stress. Hypoxia also reduced beta diversity of the gut microbiota and altered its composition.
Where NMN fell short
The organ-level results were not encouraging. NMN did not significantly affect most organ or hematological indices, so the thickened, heavier hearts stayed that way. NMN also produced a further increase in serum LDH activity. The abstract does not explain why, but a rise in a stress marker is not what a protective supplement should do, and it deserves scrutiny in follow-up work.
The authors conclude that NMN does not prevent intermittent hypoxia-induced cardiac hypertrophy at the organ level.
Where NMN did something
Under the same hypoxic conditions, NMN:
- Significantly attenuated the hypoxia-induced expression of BNP and Myh7 in the right ventricle. The molecular stress signal was dampened even though the heart was still enlarged.
- Restored spleen weight and spleen index toward normal.
- Changed the composition of the gut microbiota. The abstract does not say that NMN restored the microbiome to its original state, only that it changed it.
The authors describe this as "selective molecular and systemic effects under hypoxic exposure rather than an overall protective phenotype."
How to read this result
A lower BNP or Myh7 signal sounds good, but it is not the same as a healthier heart. In this experiment the structural problem (hypertrophy) persisted. A marker can move without changing outcomes, and with one injury marker (LDH) rising, the overall picture is unclear. Mouse tissue stress markers are also not proven predictors of benefit in people.
The spleen and gut findings are intriguing. The spleen is involved in blood-cell handling and immune responses, and both can shift under hypoxia. The gut microbiota is increasingly studied as a link between oxygen stress and whole-body physiology. But this study reports associations. It does not show that the microbiome changes caused any benefit.
Practical takeaways
Dose and timing: This study provides no human dose or timing guidance. The abstract does not report the mouse dose, and mouse doses do not translate directly to people. Do not use this paper to pick a dose.
Who might find it interesting: Researchers and clinicians following NAD+ biology, and people curious about how supplements interact with oxygen stress. Interest is not the same as a reason to take it.
Who should be cautious or skip it:
- People with sleep apnea or heart disease should not treat NMN as a substitute for CPAP, medical therapy, or cardiology follow-up. This study showed no prevention of cardiac hypertrophy, and the mice did not have sleep apnea. They were exposed to a hypoxia model.
- Altitude athletes have no evidence here of improved performance, acclimatization, or protection. The study measured none of those outcomes.
- Anyone with a heart, blood, or spleen condition, or on prescription medication, should talk to a clinician before using any supplement.
Limits worth remembering
- Animal-only: the work was done in mice, not people.
- Exploratory: the authors say so directly and call for further investigation.
- Model limits: intermittent normobaric hypoxia in mice approximates, but is not the same as, human sleep apnea or mountain exposure.
- Mixed signals: NMN reduced some markers but raised LDH and left cardiac enlargement unchanged.
- Missing details: dose, duration, and sample size are not in the abstract.
Bottom line
This study is a useful reality check for NAD+ enthusiasm. In mice exposed to intermittent low oxygen, NMN did not stop the heart from enlarging. It did turn down BNP and Myh7, normalize spleen measures, and shift gut microbiota. The authors frame this as selective effects rather than overall protection. For people, the honest answer is that we do not yet know whether any of this matters. Human trials with clinically meaningful endpoints would be needed.
This article is for information only and is not medical advice.